Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III randomized trial of 120-minute infusion gemcitabine versus 90-minute infusion gemcitabine plus docetaxel in unresectable soft tissue sarcoma: a multi-disciplinary trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society

Trial Profile

Phase III randomized trial of 120-minute infusion gemcitabine versus 90-minute infusion gemcitabine plus docetaxel in unresectable soft tissue sarcoma: a multi-disciplinary trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2006 Status change
    • 01 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top